Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial
Key Points
This research aims to assess the rebound effect on myopia progression after stopping 0.01% atropine treatment for three years.
Conducted as part of the CHAMP clinical trial.
Participants received 0.01% atropine for myopia control.
Myopia progression was monitored for four years, including one year post-treatment.
Minimal rebound in myopia progression observed after stopping treatment.
Results demonstrate sustained efficacy of 0.01% atropine for myopia control over three years.
Abstract
The Childhood Atropine for Myopia Progression (CHAMP) study was registered in clinicaltrials.gov (NCT03350620, registration date November 17, 2017).
Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial | Synapse